• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    INHALABLE COMPOSITION, PRESSURIZED CONTAINER, SIMULATED CIGARETTE, METHOD FOR THE MANUFACTURING OF A COMPOSITION, AND, USE OF THE COMPOSITION. An inhalable composition comprising: nicotine or a pharmaceutically acceptable salt or derivative thereof; a propellant; a monohydric alcohol; and a glycol and/or glycol ether, distinguished by the fact that the ratio of monohydric alcohol:glycol or glycol ether by weight is from 6:1 to 1:1.
    公开号:BR112015004231B1
    申请号:R112015004231-7
    申请日:2013-08-23
    公开日:2021-06-08
    发明作者:Alex Hearn；Stuart Bhimsen Lowe；Ritika Gupta；Chris MOYSES
    申请人:Kind Consumer Limited；
    IPC主号:
    专利说明:

    [001] The invention relates to an inhalable composition comprising nicotine, its manufacturing method and simulated cigarettes containing the inhalable composition.
    [002] Tobacco smoking is an addictive activity associated with the sensation of pleasure caused by nicotine, and reinforced by the habits and rituals of the smoker. These attributes combine to make it very difficult to give up smoking, despite the numerous adverse health effects of carbon monoxide, tar and other tobacco combustion products. It is not the nicotine itself that is harmful to health, preferably the by-products of tobacco smoke.
    [003] There are a number of smoking cessation aids currently on the market, such as nicotine skin patches, nicotine-containing gums, nicotine cartridges, and nicotine inhalers. These helpers attempt to achieve the increase in blood nicotine content provided by tobacco smoke without the associated by-products, but they do little to address the usual aspects of smoking. In addition, the detailed analysis of the supply characteristics of the smoking cessation aids above revealed a wide range of effects in terms of speed of supply, concentration, persistence, and bioavailability (Hukkanen et al., Pharmacol. Rev. 2005, 57, 79 ) . Therefore, since these adjuvants do not provide a pharmacokinetic profile similar to that of a conventional cigarette, their use in effective nicotine replacement therapy (NRT) or as an alternative to conventional recreational cigarette smoke is only very limited.
    [004] WO2011/095781 describes a simulated smoking device comprising a container containing a nicotine composition, and a refill inhaler in the shape of a cigarette. GB1528391 describes a composition comprising nicotine or a nicotine salt, a solvent for dissolving the same, a flavoring and a propellant. WO2006/004646 describes an inhalable nicotine composition containing free base nicotine with an organic acid, HFA and optionally a co-solvent. However, none of these compositions provide a user with a pharmacokinetic profile similar to that of a conventional cigarette. US2009/005423 describes an application for a nicotine composition which aims to mimic the plasma concentration of nicotine generated by cigarette smoke, i.e. a strong, fast peak in concentration after application of the composition to the oral mucosa. However, the peak provided by this composition occurs on a shorter time scale and also decays more rapidly than typically observed as a result of conventional cigarette smoke.
    [005] The present invention seeks to solve at least some of the problems associated with the prior art or at least to provide a commercially acceptable alternative solution thereof.
    [006] In a first aspect, the present invention provides an inhalable composition comprising: nicotine or a pharmaceutically acceptable salt or derivative thereof; a propellant; a monohydric alcohol; and a glycol and/or glycol ether, distinguished by the fact that the ratio of monohydric alcohol:glycol and/or glycol ether by weight is from 6:1 to 1:1.
    [007] Each aspect or embodiment as defined herein may be combined with any other aspect(s) or embodiment(s), unless expressly stated otherwise. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
    [008] The term "diameter" as used herein encompasses the largest dimension of a droplet. Droplet diameters stated here can be measured using a Malvern Spraytec device.
    [009] The term "Dv10" as used herein refers to a droplet diameter that no more than 10% by volume of the droplets of a composition has a diameter less than. The term "Dv50" as used herein refers to a droplet diameter that no more than 50% by volume of the droplets of a composition has a diameter less than. The term "Dv90" as used herein refers to a droplet diameter that no more than 90% by volume of the droplets of a composition has a diameter less than. Dv10, Dv50 and Dv90 values can be determined using a Malvern Spraytec device.
    The term "nicotine free base" as used herein refers to the form of nicotine that predominates at high pH levels, i.e., at pH levels above 7.
    The term "Cmax" as used herein refers to the maximum measured concentration of a compound, in this case nicotine, in a patient's bloodstream.
    [0012] The term "tmax" as used herein refers to the time required to reach Cmax from the administration of the compound.
    [0013] When introducing the elements of the present description or preferred embodiments thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having" are intended to be inclusive and mean that there may be additional elements other than the elements listed.
    [0014] The composition of the present invention can be delivered to a user through oral inhalation. Therefore, it is effective for use in nicotine replacement therapy (NRT) or as an alternative to recreational smoking conventional cigarettes as it mimics some of the usual aspects of smoking.
    [0015] In both conventional cigarettes and electronic cigarettes, nicotine must be heated in order to be released to the user through inhalation (to result in combustion in the case of a conventional cigarette or to result in vaporization in the case of an electronic cigarette) . Such heating results in the generation of harmful by-products, such as aldehydes, ketones, nitrosamines and heavy metals, which are then also released to the user through inhalation. In contrast, the composition of the present invention can be released via inhalation without the application of heat, which means that the levels of harmful species released to a user are significantly reduced. Furthermore, the absence of a heating step is advantageous as it avoids the need for an energy source such as a battery (in the case of an electronic cigarette) or lighting means such as matches (in the case of a conventional cigarette ).
    [0016] The glycol and/or glycol ether aids the dissolution of nicotine or a pharmaceutically acceptable salt or derivative thereof in the composition. This prevents the presence of nicotine precipitates (or other additives such as saccharin, if present) in the composition, which can cause irritation when administered to the user. In addition, the presence of glycol or glycol ether reduces the degradation of nicotine that occurs over time, thus increasing the long-term stability or "shelf life" of the composition. For example, the chromatographic analysis of the composition according to the first aspect of the present invention, after storage for six months at 40°C, 75% relative humidity, can indicate the following percentage fractions of impurity in relation to the fraction of nicotine: anabasin in no area greater than 0.3%; anatabine in no area greater than 0.3%; β-nicotyrine in no area greater than 0.3%; cotinine in no area greater than 0.3%; myosmin in no area greater than 0.3%; n-nicotine oxide in no area greater than 0.3%; nornicotine in no area greater than 0.3%. These impurity limits are within the European Pharmacopoeia specifications for the nicotine starting material, indicating the favorable degradation characteristics of the composition over the lifetime of the composition. Notwithstanding this, the European Pharmacopoeia should not be taken as limiting in any way the permissible impurities of tolerances according to this invention.
    [0017] Monohydric alcohol has a lower viscosity than a glycol or glycol ether. Therefore, the composition is able to form droplets with a smaller diameter compared to compositions where monohydric alcohol is not present. The present inventors have surprisingly found that the ratio of monohydric alcohol to glycol or glycol ether specified above results in a composition with a desired combination of both long-term stability (e.g., the composition remains as a single phase for at least one week at a temperature of 2 to 40°C) and small droplet size.
    Advantageously, when a nicotine composition having such a ratio of monohydric alcohol:glycol or glycol ether is delivered to a user through a conventional metered dose pressurized inhaler (pMDI), the composition is delivered in the form of droplets, some of which (such as, for example, at least 10% vol) have a diameter of less than 10 µm, generally less than 5 µm. Typically, most (such as, for example, at least 50% vol) of the droplets have a diameter of less than 5 µm, generally substantially all (such as, for example, at least 90% vol, or even at least 95% vol) of the droplets have a diameter of less than 5 µm. Advantageously, when administered to a user, droplets with a size of less than 10 µm tend to be deposited in the lungs rather than, for example, the oropharynx. Consequently, at least some (such as, for example, at least 10% w/w), usually substantially all (such as, for example, at least 90% w/w), of the nicotine enters the bloodstream via the pulmonary route. . This means that the composition, when inhaled orally, is better able to mimic the pharmacokinetic profile of a conventional cigarette compared to prior art nicotine compositions. Since the composition can be administered via oral inhalation and is capable of mimicking the pharmacokinetic profile of a conventional cigarette, this is particularly effective for use in NRT, or as an alternative to recreational smoking conventional cigarettes.
    [0019] Typically at least some (such as, for example, at least 10% vol) of the droplets have a size of 0.5 to 3 µm. Such drops can be deposited deep in the lung, and are therefore particularly capable of entering the bloodstream via the pulmonary route. Typically, at least some (such as, for example, at least 10% vol) of the droplets have a diameter of 0.4 to 0.5 µm. Such droplets are particularly capable of mimicking the pharmacokinetic profile of a conventional cigarette, since conventional cigarette smoke has an average particle diameter in the range of 0.4 to 0.5 µm.
    [0020] In contrast to prior art compositions, the composition of the present invention is capable of forming small diameter droplets without the use of organic acids. Consequently, the level of irritation experienced by a user of the compositions is reduced.
    [0021] When the composition of the present invention is provided to a user through one of the simulated cigarettes described below, the droplets may exhibit the following droplet size profile: Dv 90 of less than 20 µm, typically less than 5 µm, more typically less than 3, even more typically less than 2.9 µm, and/or Dv 50 less than 6 µm, typically less than 0.8 µm, more typically less than 0.7 µm, even more typically less than 0 .6 µm, and/or Dv 10 of less than 2 µm, typically less than 0.3 µm, more typically less than 0.25 µm, even more typically less than 0.2 µm.
    [0022] This particular droplet size profile is similar to the particle size profile of tobacco smoke. Therefore, the pharmacokinetic profile of the provided composition mimics that of a conventional cigarette. In particular, delivering the composition to a user generates a prolonged peak of high nicotine concentration with a short tmax, the time from the first inhalation to the maximum plasma nicotine level. As a result, the composition is highly effective for use in nicotine replacement therapy (NRT) or as an alternative to conventional recreational cigarette smoking.
    [0023] In summary, the composition of the first aspect of the present invention is, INTER ALIA, stable, causes little irritation to a user, is able to mimic the pharmacokinetic profile of a conventional cigarette, can be provided by oral inhalation and without the application of heat, and results in the release of less harmful species to a user, compared to a conventional cigarette or electronic cigarette.
    [0024] Any suitable source of nicotine can be employed. For example, nicotine can be a nicotine free base, a nicotine derivative and/or a nicotine salt. When a nicotine-free base is used, it can be used in liquid form. When a nicotine salt is used, it can be used in the form of a solution. Suitable nicotine salts include salts formed from the following acids: acetic, propionic, 1,2-butyric, methylbutyric, valeric, lauric, palmitic, tartaric, citric, malic, oxalic, benzoic, alginic, hydrochloric, chloroplatinic, silicotungsten, pyruvic, glutamic and aspartic. Other nicotine salts, such as dehydrated nicotine bitartrate, can also be used. Mixtures of two or more nicotine salts can be used. Nicotine salts can also be in liposomal encapsulation. Such encapsulation can allow the nicotine concentration of a composition to be further increased without nicotine precipitation occurring.
    [0025] As discussed above, the ratio of monohydric alcohol:glycol or glycol ether by weight results in a combination of both stability and a desired droplet size profile. Preferably, the ratio of monohydric alcohol:glycol or glycol ether by weight is from 5:1 to 1.5:1, preferably from 4:1 to 2:1, more preferably from 3:1 to 2.5 :1, even more preferably about 2.8:1.
    [0026] The glycol and/or glycol ether may be selected from among propylene glycol, polypropylene glycol and polyethylene glycol (PEG), or combinations of two or more of these. Suitably polyethylene glycols can have a molecular weight of less than 20,000 g/mol. An example of a suitable polyethylene glycol is PEG 400. Preferably, the glycol or ether glycol is propylene glycol. Propylene glycol provides the composition with a particularly desirable droplet size profile and provides greater solvation of excipients and reduces excipient degradation. Preferably, the composition comprises from 0.1 to 2% w/w propylene glycol, preferably from 0.1 to 1% w/w, more preferably from 0.2 to 0.5% w/w, even more preferably 0.25 to 0.4% w/w, even more preferably about 0.34% w/w, based on the total weight of the composition.
    [0027] Preferably, the monohydric alcohol is ethanol. Ethanol has a particularly low viscosity compared to a glycol or glycol ether, and is therefore particularly effective in allowing the composition to form small diameter droplets. Furthermore, ethanol is cheap, relatively non-harmful and readily available. Preferably, the composition comprises from 0.5 to 1.5% w/w of ethanol, preferably between 0.7 and 1.3% w/w, more preferably 0.9 to 1% w/w, even more preferably about 0.95% w/w, based on the total weight of the composition.
    Preferably, the composition further comprises a human TAS2R bitter taste receptor agonist. The use of a human TAS2R bitter taste receptor agonist induces bronchodilation, resulting in reduced levels of cough-related release. Thus, a user is better able to tolerate makeup as it causes very little irritation.
    The human bitter taste TAS2R receptor agonist can be a naturally occurring compound or a synthetic compound. Examples of suitable naturally occurring compounds include Absintin, Aloin, Amarogentin, Andrografolide, Arborescin, Arglabin, Artemorin, Camphor, Cascarillin, Cnicin, Crispolide, Ethylpyrazine, Falcarindiol, Helicin, humulone isomers, Limonin, Noscapine, papaverine, Partenoli and thiamine. Examples of suitable synthetic compounds include acesulfame K, Benzoin, Carisoprodol, chloroquine, cromolyn, dapsone, denatonium benzoate, Dimethyl thioformamide, Diphenhydramine, Divinylsulfoxide, Famotidine, saccharin, sodium benzoate, and sodium cyclamate.
    Preferably, the human bitter taste TAS2R receptor agonist is saccharin. Saccharin is particularly effective as a human bitter taste TAS2R receptor agonist, can be easily dissolved in the composition, is readily available and provides the composition with a desirable flavor profile. Preferably, the ratio of nicotine or a pharmaceutically acceptable salt or derivative thereof:saccharin by weight is from 12:1 to 5.5:1, preferably from 11:1 to 6:1, more preferably from 10:1 to 7 :1, even more preferably from 9.5:1 to 8:1, even more preferably about 8.75:1. Lower levels of saccharin result in a composition with unacceptable tolerability. Higher levels of saccharin result in acceptable tolerability, but are disadvantaged as saccharin can lead to the formation of saccharin precipitates in the composition, which can cause irritation when the composition is administered to a user or blockage when the composition is incorporated into a simulated cigarette. Such ratios also provide the composition with an optimized flavor profile.
    The propellant may be a hydrofluorocarbon, preferably a hydrofluoroalkane, even more preferably 1,1,2,2-tetrafluoroethane (HFA-134a) or 1,1,1,2,3,3-heptafluoropropane (HFC -227). Such compounds are particularly effective as propellants and have no adverse effects on the body.
    [0032] The composition may comprise at least 60% w/w propellant, preferably 90 to 99.5% w/w, preferably 96 to 99% w/w, more preferably 98 to 99% w/w , based on the total weight of the composition. The propellant is preferably liquefied.
    [0033] The composition may further comprise an aroma component. Nicotine has a long-lasting, bitter taste that can often cause a burning aftertaste. The use of an aroma component can mask this taste. Suitable flavoring components include the flavor components typically added to tobacco products. Examples include products of carotenoids, alkenols, aldehydes, esters and delta-lactone flavor constituents. Suitable carotenoid products include beta ionone, alpha ionone, beta-damasconone, beta-damascenone, oxo-edulan I, oxo-edulan II, teaspirone, 4-oxo-beta-ionone, 3-oxo-alpha-ionone, dihydroactinodiolide , 4-oxoisophorone, safranal, beta-cyclocitral. Suitable alkenols include C4 to C10 alkenols, preferably C5 to C8 alkenols. Specific examples include: cis-2-penten-1-ol, cis-2-hexen-1-ol, trans-2-hexen-1-ol, trans-2-hexen-1-ol, cis-3-Hexen- 1-ol, trans-3-hexen-1-ol, trans-2-hepten-1-ol, cis-3-hepten-1-ol, trans-3-hepten-1-ol, cis-4-hepten- 1-ol, trans-2-octen-1-ol, cis-3-octen-1-ol, cis-5-octen-1-ol, 1-octen-3-ol and 3-octen-2-ol. Suitable aldehydes include benzaldehyde, glucose and cinnamaldehyde. Suitable esters include allyl hexanoate, benzyl acetate, bornyl acetate, butyl butyrate, ethyl butyrate, ethyl hexanoate, ethyl cinnamate, ethyl formate, ethyl heptanoate, ethyl isovalerate, ethyl lactate, nonanoate. ethyl, ethyl valerate, geranyl acetate, geranyl butyrate, isobutyl acetate, isobutyl formate, isoamyl acetate, isopropyl acetate, linalyl acetate, linalyl butyrate, linalyl formate, methyl acetate, methyl anthranilate, methyl benzoate, benzyl methyl acetate, methyl butyrate, methyl cinnamate, methyl pentanoate, phenyl methyl acetate, methyl salicylate (oil of wintergreen), nonyl caprylate, octyl acetate, octyl butyrate, amyl acetate (pentyl acetate), pentyl hexanoate, pentyl pentanoate, propyl ethanoate, propyl isobutyrate, terpenyl butyrate, ethyl formate, ethyl acetate, ethyl propionate, ethyl butyrate, et valerate yl, hexyl hexanoate, ethyl heptanoate, ethyl octanoate, ethyl nonanoate, ethyl decanoate, ethyl dodecanoate, ethyl myristate, ethyl palmitate. Suitable delta-lactone flavoring constituents include delta-hexalactone, delta-octalactone, delta-nonalactone, delta-decalactone, delta-undecalactone, delta-dodecalactone, Massoia lactone, jasmine lactone and 6-pentyl-alpha-pyrone. Flavoring components can serve to mask the unpleasant nicotine taste.
    [0034] The flavoring component is preferably menthol and/or vanillin. The presence of menthol, together with saccharin, reduces the irritation experienced by a user. Preferably, the composition comprises up to 0.1% w/w menthol, preferably from 0.01% w/w to 0.08% w/w, more preferably between about 0.02% w/w of 0.06% w/w, even more preferably from 0.03% w/w to 0.05% w/w, even more preferably about 0.04% w/w, based on the total weight of the composition.
    [0035] The composition may comprise from 0.001% w/w to 0.045% w/w of nicotine or a pharmaceutically acceptable salt or derivative thereof, preferably from 0.01% w/w to 0.045% w/w, more than preferably between 0.015% w/w to 0.04% w/w, even more preferably between about 0.02% w/w to 0.035% w/w, even more preferably between 0.025% w/w of 0.0 03% w/w, more preferably about 0.028% w/w, based on the total weight of the composition. This composition provides similar effects to a "low strength" nicotine cigarette.
    The composition may comprise from 0.04% w/pa 0.07% w/w of nicotine or a pharmaceutically acceptable salt or derivative thereof, preferably between 0.045% w/pa 0.065% w/w, more than preferably 0.05% w/pa 0.06% w/w, even more preferably between 0.054% w/pa 0.058% w/w, even more preferably about 0.056% w/w, based on the total weight of makeup. This composition provides similar effects to a "medium strength" nicotine cigarette.
    The composition may comprise from 0.065% w/pa 0.1% w/w of nicotine or a pharmaceutically acceptable salt or derivative thereof, preferably from 0.07% w/pa 0.095% w/w, more than preferably from 0.075% w/w to 0.09% w/w, even more preferably from 0.08% w/w to 0.088% w/w, even more preferably from about 0.084% w/w, based on the total weight of makeup. This composition provides similar effects to a "high strength" nicotine cigarette.
    [0038] A particularly preferred composition comprises, based on the total weight of the composition: from 0.03 to 0.05% w/w menthol, preferably about 0.04% w/w, from 0 .25 to 0.4% w/w propylene glycol preferably about 0.34% w/w, from 0.9 to 1% w/w ethanol, preferably about 0.95% w/w , saccharin, and/or: (i) from 0.025% w/w to 0.03% w/w nicotine or a pharmaceutically acceptable salt or derivative thereof, preferably from about 0.028% w/w, or(ii) to from 0.054% w/w to 0.058% w/w of nicotine or a pharmaceutically acceptable salt or derivative thereof, preferably from about 0.056% w/w, or (iii) from 0.08% w/w to 0.088% w/w of nicotine or a pharmaceutically acceptable salt or derivative thereof, preferably of about 0.084% w/w, the perfect balance being HFA-134a, wherein the ratio of nicotine to saccharin by weight is 9.5: 1 to 8:1, preferably about 8.75:1. Such a composition presents a particularly desirable combination of the above-described advantages.
    [0039] Preferably the total solvent content, i.e. the total content of monohydric alcohol and glycol and/or glycol ether, is less than 35% w/w, preferably less than 6% w/w, more preferably from 0.1% w/w to 2.5% w/w, based on volume by weight of the composition. Reducing the total solvent content of the composition reduces its viscosity, meaning it is better able to form more favorable droplet sizes.
    [0040] Preferably, the composition comprises less than 0.01% w/w nicotinic acid, more preferably less than 0.005% w/w, even more preferably less than 0.001% w/w nicotinic acid, based on the total weight of the composition. More preferably, the composition comprises substantially no nicotinic acid. The presence of nicotinic acid can result in the formation of precipitates in the composition.
    [0041] Compositions according to the first aspect may "consist" of the components recited above. The compositions according to the first aspect may "consist" of the components recited above, together with any unavoidable impurities.
    [0042] In a second aspect, the present invention provides a pressurized container containing the composition of the first aspect.
    [0043] The pressurized container of the second aspect of the present invention may be used to release a gaseous stream of the nicotine composition of the first aspect to a user. For example, the pressurized container may be provided with means for delivering the contents of the container to a user's lungs. Such means may take the form of a button, trigger or breath activated mechanism. The pressurized container can be used to deliver an unmeasured dose of nicotine to the user. This can be advantageous over prior art NRT methods, such as conventional inhalers, nasal sprays, patches and lozenges currently on the market, because it can allow autonomy in nicotine replacement regulation, in which the user can regulate the amount of nicotine from the composition he or she wants to inhale. Furthermore, the pressurized container can be used as an alternative to conventional recreational cigarette smoking.
    [0044] The pressurized container of the present invention can be used to release the composition to a user without the need for a separate source of energy. For example, the composition can be released without requiring heating of the substrates, combustion of material or a battery-powered electrical current. As discussed above, this can lead to a reduction in the levels of harmful by-products released to a user.
    [0045] The pressurized container of the present invention may take the form of a pressurized package, for example a pressurized aluminum can. The container can be fully recyclable and/or reusable. The container can be refilled as required by a vending machine or a larger container containing the desired composition under a high pressure gradient. In one embodiment, the container is an AW5052 aluminum can.
    [0046] The pressurized container may be a simulated cigarette.
    [0047] The pressurized container may be capable of dispensing the composition as a mixture of aerosol droplets. Preferably, the blend has a particle size distribution that is similar to tobacco smoke. The mixture may have the appearance of a vapor or smoke.
    [0048] The pressurized container may be pressurized at a pressure of between 3 x 105 Pa to 1.5 x 107 Pa, preferably between 5 x 105 Pa to 2 x 106 Pa, more preferably from 5.5 x 105 Pa to 1 x 106 Pa, even more preferably at about 6 x 105 Pa.
    [0049] The pressurized container can be used to refill a sham cigarette, in particular the sham cigarette of the third aspect of the present invention described below.
    [0050] The contents of the pressurized container may comprise from 16 to 18 mg of nicotine, preferably about 17.18 mg of nicotine; from 7 to 9 mg of menthol, preferably about 8.176 mg of menthol; from 1 to 3 mg of saccharin, preferably about 1.963 mg of saccharin; from 68 to 72 mg of propylene glycol, preferably about 69.5 mg of propylene glycol; from 190 to 200 mg of ethanol, preferably about 194.2 mg of ethanol; and from 18 to 22 g of HFA-134a, preferably about 20.15 g of HFA-134a. Alternatively, the contents of the pressurized container can comprise from 10 to 12 mg of nicotine, preferably about 11.45 mg of nicotine; from 7 to 9 mg of menthol, preferably about 8.176 mg of menthol; 1.1 to 1.4 mg of saccharin, preferably about 1.288 mg of saccharin; 68 to 72 mg of propylene glycol, preferably about 69.5 mg of propylene glycol; from 190 to 200 mg of ethanol, preferably about 194.2 mg of ethanol; from 18 to 22 g of HFA-134a, preferably about 20.16 g of HFA-134a. Alternatively, the contents of the pressurized container can comprise from 5 to 7 mg of nicotine, preferably about 5.73 mg of nicotine; from 7 to 9 mg of menthol, preferably about 8.176 mg of menthol; from 0.5 to 0.8 mg saccharin, preferably about 0.654 mg saccharin; 68 to 72 mg of propylene glycol, preferably about 69.5 mg of propylene glycol; 190 to 200 mg of ethanol, preferably about 194.2 mg of ethanol; and from 18 to 22 g of HFA-134a, preferably about 20.16 g of HFA-134a. Alternatively, the contents of the pressurized container may comprise about 7 to 9 mg of menthol, preferably 8.176 mg of menthol; from 0.1 to 0.3 mg of saccharin, preferably about 0.204 mg of saccharin; 68 to 72 mg of propylene glycol, preferably about 69.5 mg of propylene glycol; from 190 to 200 mg of ethanol, preferably about 194.2 mg of ethanol; and from 18 to 22 g of HFA-134a, preferably about 20.17 g of HFA-134a.
    [0051] The pressurized container can be used to refill a simulated cigarette. Such a "refill" container may comprise from 0.6 to 0.7 mg of nicotine, preferably about 0.672 mg of nicotine; from 0.2 and 0.4 mg of menthol, preferably about 0.32 mg of menthol; 0.07 to 0.09 mg of saccharin, preferably about 0.077 mg of saccharin; 2.5 to 2.9 mg of propylene glycol, preferably about 2.72 mg of propylene glycol; from 7 to 9 mg of ethanol, preferably about 7.6 mg of ethanol; and 760 to 800 mg of HFA-13a, preferably about 788.6 mg of HFA-134a. Alternatively, such a refill may comprise 0.4 to 0.5 mg of nicotine, preferably about 0.448 mg of nicotine; between 0.2 to 0.4 mg of menthol, preferably about 0.32 mg of menthol; from 0.04 to 0.06 mg of saccharin, preferably about 0.051 mg of saccharin; from 2.5 to 2.9 mg of propylene glycol, preferably about 2.72 mg of propylene glycol; from 7 to 9 mg of ethanol, preferably about 7.6 mg of ethanol; and from 760 to 800 mg of HFA-134a, preferably about 788.9 mg of HFA-134a. Alternatively, each refill may comprise from 0.1 to 0.3 mg of nicotine, preferably about 0.224 mg of nicotine, from 0.2 and 0.4 mg of menthol, preferably about 0.32 mg of menthol; from 0.01 to 0.03 mg of saccharin, preferably about 0.026 mg of saccharin, from 2.5 to 2.9 mg of propylene glycol, preferably about 2.72 mg of propylene glycol, from 7 to 9 mg of ethanol , preferably about 7.6 mg of ethanol, and from 760 to 800 mg of HFA-134a, preferably about 789.1 mg of HFA-134a. Alternatively, such a new refill may comprise from 0.2 and 0.4 mg of menthol, preferably about 0.32 mg of menthol, of 0.007 mg and 0.009 mg of saccharin, preferably about 0.008 mg of saccharin, of 2.5 to 2.9 mg of propylene glycol, preferably about 2.72 mg of propylene glycol; from 7 to 9 mg of ethanol, preferably about 7.6 mg of ethanol; and from 760 to 800 mg of HFA-134a, preferably about 789.4 mg of HFA-134a.
    [0052] The nicotine in the contents of the pressurized container described above can, of course, be replaced with a pharmaceutically acceptable salt or derivative thereof.
    [0053] In a third aspect, the present invention provides a simulated cigarette device comprising: a housing; a pressurized reservoir of inhalable composition within the housing; an outlet for the inhalable composition from the reservoir and out of the housing, the outlet being configured to eject inhalable composition therefrom in the form of droplets, at least some of the droplets having a diameter of 10 µm or less; and an outlet valve for controlling the flow of the inhalable composition through the outlet, wherein the inhalable composition is in accordance with the first aspect.
    [0054] For example, the outlet can be configured to eject inhalable composition therefrom in the form of droplets, at least 1% by volume of the droplets having a diameter of 10 µm or less.
    [0055] Preferably, most droplets (such as at least 50% vol) have a diameter of 10 µm or less, more preferably substantially all droplets (such as at least 90% vol) have a diameter of 10 µm or less. Preferably at least some of the droplets (such as at least 1% vol) have a diameter of 5 µm or less, preferably most droplets (such as at least 50% vol ) has a diameter of 5 µm or less, more preferably substantially all of the droplets (such as at least 90% vol) have a diameter of 5 µm or less.
    [0056] Preferably, the outlet valve is a breath activated valve.
    [0057] Preferably, the simulated cigarette further comprises a capillary plug extending from the proximity of the outlet valve into the reservoir, filling at least 50% of the reservoir volume and being configured to spread the composition inhalable towards the exit.
    [0058] Preferably, the simulated cigarette has a breath-operated valve and the housing has an outlet end and an opposite end and the simulated cigarette further comprises: a composition flow path for composition flow from the reservoir to the along the fluid path and out of the outlet at the outlet end of the housing; a flexible diaphragm within the housing that defines an air flow path from an air inlet to an air outlet at the outlet end of the housing a valve element movable with the diaphragm and biased by a pressure force to a position in which it closes the composition flow path; wherein suction at the outlet end causes a flow through the air flow path providing a pressure differential over the valve element thereby raising the valve element against the pressure force to open the composition flow path; and wherein the pressure force is arranged to close the flow path of the composition once suction ceases.
    [0059] Preferably, the simulated cigarette has a breath operated valve and the breath activated valve is an uncalibrated valve between the outlet and the reservoir, the breath activated valve comprising a flow path extending from the reservoir to the outlet end, at least a portion of the flow path being a deformable tube, and a clamping element that squeezes the deformable tube closed when no suction force is applied to the device and releases the tube to open the flow path when suction is applied at the outlet to provide uninterrupted flow from the reservoir to the outlet. This dummy cigarette will then be referred to as a dummy "choke valve" cigarette.
    [0060] Preferably, the simulated cigarette further comprises a refill valve in communication with the reservoir, through which the reservoir can be refilled. The sham cigarette can be refilled from a container in accordance with the second aspect of the present invention.
    [0061] Preferably, the size of the reservoir, the pressure within the reservoir and the size of the outlet at its narrowest point are arranged so that when the outlet valve is fully open, the reservoir will be discharged in less than 30 seconds .
    [0062] Preferably, the simulated cigarette is configured to eject droplets of composition resulting therefrom, wherein at least 97% by volume of the droplets have a diameter of less than 10 µm, preferably at least 98% by volume, more preferably at least 98.5% by volume, even more preferably at least 99% by volume. Droplets smaller than 10 µm in diameter are deposited in the lungs, meaning that a pharmacokinetic profile similar to that of a conventional cigarette is provided.
    [0063] Preferably, the simulated cigarette is configured to eject droplets of composition therefrom having the following size profile: Dv 90 of less than 20 µm, preferably less than 5 µm, more preferably less than 3 µm, even more preferably less than 2.9 µm, and/or Dv 50 of less than 6 µm, preferably less than 0.8 µm, more preferably less than 0.7 µm, even more preferably less than 0.6 µm, and/ or Dv 10 of less than 2 µm, preferably less than 0.3 µm, more preferably less than 0.25 µm, even more preferably less than 0.2 µm.
    [0064] Therefore, in one embodiment, the simulated cigarette is configured to eject droplets with the following size profile: Dv 90 < 20 μm, Dv 50 < 6 μm and Dv 10 < 2 μm; preferably with the following size profile: Dv 90 <5 µm, Dv 50 < 0.8 µm and Dv 10 < 0.3 µm; more preferably, with the following size profile: Dv 90 < 3 µm, Dv 50 < 0.7 µm and Dv 10 < 0.25 µm; even more preferably, with the following size profile: Dv 90 < 2.9 µm, Dv 50 < 0.6 µm and Dv 10 < 0.2 µm.
    [0065] Such a profile of a size similar to that of a conventional cigarette, which means that the pharmacokinetic profile provided more closely mimics that of a conventional cigarette.
    [0066] The sham cigarette can provide the user with an arterial nicotine Cmax of up to 15 ng/ml, typically 2 to 10 ng/ml, or even 4 to 8 ng/ml. Cmax values greater than about 2 ng/ml provide the user with "dizziness" as experienced when smoking a conventional cigarette.
    The sham cigarette can provide these Cmax values, with a tmax of 10 seconds to 20 minutes, typically 5 minutes to 15 minutes, often around 12 minutes. Compared to prior art simulated cigarette devices, such tmax values are closer to those exhibited in conventional cigarettes. Therefore, the present invention more closely mimics the pharmacokinetic profile of a conventional cigarette, and is therefore particularly effective for use in NRT or as an alternative to recreational smoking conventional cigarettes.
    [0068] Preferably, the simulated cigarette is configured to eject the composition therefrom at a rate of 0.5 to 3 liters per minute. This ratio is similar to the ratio of smoke ejected from a conventional cigarette. Preferably, the sham cigarette is configured to provide an inhalation resistance of from 1 to 7 kPa, preferably about 4 kPa. This inhalation resistance is similar to that provided by a conventional cigarette. When the simulated cigarette is configured to have the above ejection rate and/or inhalation resistance, preferably, the simulated cigarette is configured to deliver nicotine to a user at a rate in the range of 0.01 to 0.06 mg/ml. This is less than a conventional cigarette. However, since the usual aspects of smoking have been mimicked by the ejection and inhalation resistance ratio above, a user will experience the same level of satisfaction with a lower level of inhaled nicotine compared to conventional smoking cessation aids.
    [0069] In a fourth aspect, the present invention provides a method of manufacturing the composition of the first aspect, the method comprising: preparing a premix comprising a polyhydric alcohol and a glycol and/or glycol ether, and optionally , a TAS2R taste receptor agonist and/or flavoring agent, wherein the ratio of polyhydric alcohol:glycol or glycol ether by weight is from 6:1 to 1:1; addition of nicotine or a pharmaceutically acceptable salt or derivative the same for the premix to obtain a mixture containing nicotine; and adding a propellant to the nicotine-containing mixture.
    [0070] If nicotine is added before the polyhydric alcohol or glycol and glycol ether are combined, then precipitation of nicotine can occur. Likewise, if the composition comprises other components, such as a flavoring component or a TAS2R taste receptor agonist, then these components must be thoroughly mixed into the premix before the nicotine is added in order to avoid nicotine precipitation. In particular, it has been found that when the composition comprises menthol, the menthol must be fully dissolved in the premix before the nicotine is added in order to avoid precipitation of the nicotine.
    [0071] When the composition is to include a TAS2R taste receptor agonist and/or a flavoring component, preferably the polyhydric alcohol or glycol and glycol ether are combined before the TAS2R taste receptor agonist and/or a flavoring component to be added. This prevents precipitation of the flavoring or taste receptor agonist component TAS2R.
    In a fifth aspect, the present invention provides a composition comprising: nicotine or a pharmaceutically acceptable derivative or a salt thereof; a monohydric alcohol; and a glycol and/or glycol ether, distinguished by the fact that the ratio of monohydric alcohol: glycol or glycol ether by weight is from 6: 1 to 1:1.
    [0073] Such a composition can be used as an intermediate in preparing the composition of the first aspect. Preferred additional components, concentrations and ratios of the first aspect are also preferred in the third aspect.
    [0074] In a sixth aspect, the present invention provides a sham cigarette configured to provide the user thereof with a venous nicotine Cmax of up to 15 ng/ml and/or with a tmax of from 10 seconds to 20 minutes.
    [0075] In a seventh aspect, the present invention provides a method of treating a condition selected from: nicotine dependence and neurodegenerative diseases such as Alzheimer's and Parkinson's disease, using the composition of the first aspect of the present invention.
    [0076] Embodiments of the first aspect of the present invention may have the following advantages over the prior art. The identity and relative concentrations of solvents in the composition are optimized to provide greater long-term stability (distinguished by, for example, no precipitates, lack of phase separation, negligible formation of by-products, lower incidence of impurities), plus plus the identity and relative concentrations of volatile and non-volatile solvents in the composition are optimized in such a way that the aerosol generated through a suitable delivery method is deposited in the lungs (distinguished, eg, optimized particle/droplet size distribution) , as soon as the nicotine contained in it enters the bloodstream through the pulmonary route. In addition, the concentration of TAS2R bitter flavors and agonists in the composition can be optimized to improve palatability and tolerability (distinguished by, for example, lower incidence of adverse events, such as coughing and respiratory tract/throat irritation, which can inhibit the effective release of the composition to the lungs) so that the user will be inclined to repeatedly administer the composition in the form of a cigarette smoker. Still further, the composition can be administered to the user via a simulated cigarette device that effectively mimics the "feel" of smoking. Still additionally, the manufacturing method and order of addition of reagents is optimized such that nicotine, TAS2R bitter taste agonists, and/or flavorings can be incorporated at desired levels, preventing the formation of precipitates. Furthermore, the composition can be administered in such a way that clinical outcomes (distinguished by, for example, favorable score scores and cigarette-like tmax) can be achieved with a lower released dose of nicotine than has previously been possible, with a dosage regimen that is familiar to a smoker, thus improving the user experience and making the composition more effective as an alternative to combustible tobacco products. An additional advantage can be realized when using the composition as a treatment for medical conditions.
    [0077] The present invention is described by way of example in relation to the following non-limiting figures.
    [0078] Figure 1 shows a graph of mean arterial plasma nicotine concentrations over time for those administered the "high", "medium" or "low" strength nicotine compositions of the first aspect of the present invention.
    [0079] Figure 2 shows a graph of mean craving VAS scores over time for subjects who administered the "high", "medium" or "low" resistance nicotine compositions of the first aspect of the present invention.
    [0080] Figure 3 shows graphs of arterial and venous nicotine concentrations measured at intervals after inhalation of a "high" strength nicotine composition of the first aspect of the present invention.
    [0081] Figure 4 shows graphs of arterial and venous nicotine concentrations measured at intervals after inhalation of a "medium" strength nicotine composition of the first aspect of the present invention. Examples
    [0082] The invention will now be described with reference to the following non-limiting examples.
    [0083] The following starting materials were used: Saccharin (Ph. Eur.) Propylene glycol (EP grade) Menthol (Ph Eur.) Ethanol (100% BP, Ph. Eur.) Nicotine (Ph. Eur.)HFA-134a ( CPMP 1994)
    The starting materials were added to a mixing vessel in the following order: (i) 5.14 g of saccharin, (ii) 227.0 g of propylene glycol, (iii) 32.5 g of menthol and ( iv) 774.0 g of ethanol. The mixture was then stirred at 600 rpm for 15 minutes until the menthol granules had completely dissolved and a clear liquid was observed. 45.6 g of nicotine was then added to the mixture and stirring was maintained at 600 rpm for a further 10 minutes. The resulting mixture was then added to a pressure vessel that had been purged with HFA-134a. The vessel was then sealed before being cooled until the internal temperature reached 8 to 12°C, at which point the temperature was maintained. Approximately 40 kg of HFA-134a was then released into the vessel before magnetic stirring at 210 rpm began. HFA continued to be released into the vessel until a total of 80 kilograms had been added, at which point the composition was stirred at 210 rpm for a further 110 minutes. During further agitation, the pressure was controlled to ensure that it did not exceed 4.5 bar, and that the final pressure was between 3 to 4 bar. After shaking, the composition was dispensed into cans.
    [0085] Varying the method by adding nicotine either before the saccharin was added or before the menthol was completely dissolved resulted in the precipitation of nicotine. Stability
    [0086] A number of compositions were prepared with different ethanol:propylene glycol ratios. The stability of the compositions under various conditions was determined visually, and the results are shown in Tables 1 and 2. Compositions with ethanol:propylene glycol ratios less than 1:1 separated into two phases within one week.
    Table 1 - Stability data for various ratios of ethanol: propylene glycol. (Samples 1 and 2 are comparative examples).

    Table 2 - Stability data for various ratios of ethanol: propylene glycol. The term "soluble" indicates that no precipitates were observed. Droplet Size Profile
    [0087] The following composition was prepared: 0.04% w/w menthol, 0.006% w/w saccharin, 0.34% w/w propylene glycol, 0.95% w/w ethanol, 0.056% w/w nicotine, remaining HFA-134a.
    [0088] The composition was inserted into nine simulated choke valve cigarettes. Five doses were emitted from each device and the droplet size profile of each was measured using a Malvern Spraytec device. The results are shown in Table 3 below:
    Table 3 - Droplet size profile. impurities
    [0089] The following composition was prepared: 0.04% w/w menthol, 0.0032% w/w saccharin, 0.34% w/w propylene glycol and 0.95% w/w ethanol, 0.028% w/w nicotine, remaining HFA-134a.
    [0090] The composition was then filled into a pressurized container. The percentage by volume of impurities with respect to nicotine concentration was evaluated by chromatography at both the refill time and after six months. The results are shown in Table 4 below:
    Table 4 - Stability data (inverted, 40°C/75% relative humidity). N = 1, 2 and 3 refer to different pressurized containers from the same batch of composition. clinical study
    [0091] This was a three-part study to determine the safety, tolerance and pharmacokinetics of orally inhaled nicotine through the simulated choke valve cigarette, which contained compositions according to the first aspect of the present invention.
    [0092] The following compositions were studied: (1) "high" nicotine: 0.04% w/w menthol 0.0096% w/w saccharin, 0.34% w/w propylene glycol, 0.95 % w/w ethanol, 0.084% w/w nicotine and 98.5764% w/w HFA-134a.(2) "average" nicotine: 0.04% w/w menthol 0.0063% w/ saccharin powder, 0.34% w/w propylene glycol 1, 0.95% w/w ethanol, 0.056% w/w nicotine and 98.6077% w/w HFA-134a.(3) " low" nicotine: 0.04% w/w menthol 0.0032% w/w saccharin, 0.34% w/w propylene glycol, 0.95% w/w ethanol, 0.028% w/w nicotine and 98.6388% w/w HFA-134a.
    [0093] Part A was to assess the safety, tolerance, and arterial pharmacokinetics of a single dose of orally inhaled nicotine composition via the simulated choke valve cigarette for the three dose levels. Part B was to assess the venous pharmacokinetics of a single dose of nicotine inhaled orally through the sham valve choke. Part C was to assess the safety, tolerance, and pharmacokinetics of repeated doses of orally inhaled nicotine via sham valve choke.
    [0094] This study was conducted on participating men and women who smoked at least ten manufactured cigarettes per day in the past year. The study was conducted at a center in Perth, Australia, and was performed on healthy volunteers.
    [0095] Screening assessments were performed up to six weeks prior to early study dosing and eligible participants included in the study were re-evaluated for continued study suitability prior to the planned study dosing on day 1. Any enrolled participants who were discontinued prior to study the dosage were replaced.
    [0096] A minimum of sixty (60) healthy volunteers were planned for enrollment in the three parts of the study. Participants were unable to participate in more than one part of the study.
    [0097] Part A: This was a single-blind, randomized, multidose study to assess the tolerance and arterial pharmacokinetics of orally inhaled nicotine via the choke valve sham cigarette in three doses of 0.028% w/w (low) nicotine ), 0.056% w/w (medium) and 0.084% w/w (high). It was necessary to resort to arterial blood sampling for this part of the study to investigate the speed of release to the systemic circulation. Eighteen (18) participants were enrolled in treatment group A, and were randomized to receive 2 of 3 doses via the choke valve sham cigarette on a single study day. Nicotine dose levels were 0.028% w/w (low), 0.056% w/w (medium) and 0.084% w/w (high).
    [0098] The eighteen (18) participants were divided into three groups with each containing six participants. One group received the low nicotine dose followed by the medium nicotine dose; one group received the low nicotine dose, followed by the high nicotine dose; and one group received the medium nicotine dose followed by the high nicotine dose. The first dosing took place at approximately eight hours, and the second at approximately 1:30 pm. This was to ensure that circulating nicotine concentrations from the first dose had reached baseline levels through excretion before the second dose was inhaled. Participants were unaware of the dose level of orally inhaled nicotine through the simulated choke valve cigarette they should be receiving.
    [0099] At the end of Part A, the pharmacokinetic, safety and tolerance data obtained from Part A were analyzed to determine which two of the three dose levels were studied for use in Part B.
    [00100] Part B: This was an open-label, 3-way, randomized/single-blind, open-label crossover study to evaluate the venous pharmacokinetics of two doses of orally inhaled nicotine via sham valve cigarette smoking. Participants were unaware of the nicotine dose level of the simulated choke valve cigarette they received.
    [00101] Twenty-four (24) participants were enrolled in treatment group B. Each participant participated in the confined clinical trial unit for three consecutive days to receive a full refill of choke valve sham cigarette at one nicotine dose level in one day, a full refill of the simulated choke valve cigarette at a second nicotine dose level on the second day and a treatment of a conventional nicotine inhaler (10 mg) on a third day. The order in which treatment was to be received was randomized.
    [00102] At the end of Part B, the PK, safety and tolerance data obtained from Parts A and B were analyzed to determine which of the two dose levels studied was to be used in Part C.
    [00103] Part C: This was an open-label study to assess the tolerance and venous pharmacokinetics of repeated doses of orally inhaled nicotine via the sham valve sham cigarette with a dose of nicotine.
    [00104] Eighteen (18) participants were enrolled in treatment group C. Each participant received repeated doses of nicotine over a one-day period. All participants received the same dose of nicotine through the simulated choke-valve cigarette. A full refill of the simulated choke valve cigarette was inhaled every hour for 12 hours. The first dosage took approximately eight hours. Population Study:
    Pharmacokinetic data:
    [00105] The pharmacokinetic data are illustrated in Figure 1 and are presented in Table 6. From Figure 1 it can be seen that the arterial sampling times were sufficient to clearly define the pharmacokinetic profile, and in particular, to define the nicotine of the plasma Cmax. All intervals are taken from the beginning of the inhalation which took approximately 2 minutes to complete. The first sampling time point at +2 minutes already reveals nicotine absorption in arterial blood. For example, for the resistance of 0.056% w/w the mean arterial nicotine concentration had risen from the pre-dose from zero to 2.06 ng/ml to 2 minutes, ie, already in more than half of the eventual Cmax. From this it can be inferred that plasma nicotine was rising rapidly during the inhalation process. Mean maximum nicotine concentrations were 2.11, 3.73 and 4.38 ng/ml at low, medium and high resistance, respectively, and corresponding tmax were 10.2, 7.3 and 6.5 minutes after the start of inhalation.
    [00106] The generation of arterial pharmacokinetic data is not without some technical difficulties in terms of vascular access, but in this part of the study the arterial data are valuable in demonstrating how quickly nicotine reaches the arterial circulation. Since the composition is orally inhaled, a conclusion that follows is that this rate of nicotine release indicates that there is a degree of pulmonary release, since buccal release, such as provided by a conventional nicotine inhaler , is much slower.
    Table 6 - Pharmacokinetic data (arterial concentration). AUCall refers to "area under the curve". Pharmacodynamic data:
    [00107] The pharmacodynamic measurements included in all four parts of the study are the repeated assessments of anxiety using a visual analogue scale (VAS) and the Brief Impulse Smoking Questionnaire (QSU-B). Pharmacodynamic data based on VAS are shown in Figure 2.
    [00108] Inhaling a nicotine aerosol from the simulated choke valve cigarette has a clear effect of reducing craving, which results in all four parts of the study. In part A, the craving quickly dropped on inhalation and then gradually returned to baseline levels over the next 5 hours. No statistical tests were performed on part A, but the response pattern is consistent across all 3 strengths of nicotine dosages.
    [00109] It is notable that there was no clear dose-response relationship for part A craving and this perhaps reflects the importance for the ritual of hand to mouth smoking and throat capture, as well as the pharmacological effect of augmentation of circulating nicotine concentrations. The QSU-B showed a consistent pattern for the anxiety VAS with component and total scores at its lowest post-dose of 40 minutes for the low dose (0.028% w/w), and for post-dose 20 minutes for the medium dose (0.056% w/w) and (0.084% w/w) high dose. This suggests that although the low dose has a positive effect on the smoking boost, it takes longer to do the same than the medium and high doses. Arterial vs venous graphs:
    [00110] Figures 3 and 4 show graphs of arterial and venous nicotine concentrations experienced by users of "high" resistance and "medium" resistance compositions. These graphs indicate the speed at which nicotine reaches the arterial circulation. Since the composition is orally inhaled, the rate of nicotine release is consistent with a degree of pulmonary delivery. Oral delivery, as provided by commercially available inhalers, is much slower. Tolerance
    [00111] All adverse events were classified as mild or moderate, there were no adverse events reported as severe. There were no significant adverse events (AE) or deaths throughout the study, and no participant discontinued treatment due to an AE.
    [00112] Oral paresthesia was by far the most frequently reported treatment-related adverse event (TEAE) that was reported throughout the study, with a total of 40 participants (68%) reporting oral paresthesia at least once. Seventeen (17) of 59 participants (29%) reported throat irritation, 9 participants (15%) reported headache, 8 participants (14%) reported oral hypoesthesia, and 6 participants (10%) reported dizziness as a related TEAE . The remaining TEAEs occurred in less than 10% of the total patient population.
    [00113] A summary of the results is presented in Table 7 below.

    [00114] The foregoing detailed description has been given by way of explanation and illustration, and is not intended to limit the scope of the appended claims. Many variations of the presently preferred embodiments illustrated herein will be apparent to one skilled in the art, and remain within the scope of the appended claims and their equivalents.
    权利要求:
    Claims (13)
    [0001]
    1. Inhalable composition, comprising: nicotine or a pharmaceutically acceptable salt thereof; at least 90% w/w of a propellant, wherein the propellant is a hydrofluorocarbon; a monohydric alcohol; e 0.1 to 1% w/w of a glycol and/or glycol ether, based on the total weight of the composition, wherein the glycol and/or glycol ether is a propylene glycol, characterized by the fact that the ratio of monohydric alcohol:glycol or glycol ether by weight is from 3:1 to 1:1.
    [0002]
    2. Composition according to claim 1, characterized in that the ratio of monohydric alcohol: glycol or glycol ether by weight is from 3:1 to 1.5:1.
    [0003]
    3. Composition according to any one of claims 1 or 2, characterized in that: the monohydric alcohol is ethanol, preferably wherein the composition comprises from 0.5 to 1.5% w/w of ethanol, with based on the total weight of the composition, and/or the composition further comprises a human TAS2R bitter taste receptor agonist, preferably wherein the human TAS2R bitter taste receptor agonist is saccharin, more preferably wherein the ratio of nicotine or a pharmaceutically acceptable salt of the same: saccharin by weight is from 12:1 to 5.5:1, and/or the composition further comprises a flavor component, preferably menthol or vanillin, more preferably wherein the composition comprises up to 0.1% w/w menthol , based on the total weight of the composition.
    [0004]
    4. Composition according to any one of claims 1 to 3, characterized in that it comprises: from 0.001% w/w to 0.045% w/w of nicotine or a pharmaceutically acceptable salt thereof, based on the total weight of the composition; or, from 0.04% w/w to 0.07% w/w nicotine or a pharmaceutically acceptable salt thereof, based on the total weight of the composition; or, from 0.065% w/w to 0.1% w/w nicotine or a pharmaceutically acceptable salt thereof, based on the total weight of the composition.
    [0005]
    5. Composition according to claim 1, characterized in that it comprises, based on the total weight of the composition: from 0.03 to 0.05% w/w of menthol, from 0.25 to 0.4% w /w propylene glycol, from 0.9 to 1% w/w ethanol, saccharin, and also: (i) from 0.025% w/w to 0.03% w/w nicotine or a pharmaceutically acceptable salt thereof, or (ii) from 0.054% w/w 0.058% w/w nicotine or a pharmaceutically acceptable salt thereof, or (iii) from 0.08% w/w 0.088% w/w nicotine or a pharmaceutically acceptable salt thereof , the balance being HFA-134a, wherein the ratio of nicotine or a pharmaceutically acceptable salt thereof to saccharin by weight is from 9.5:1 to 8:1.
    [0006]
    6. Pressurized container, characterized in that it contains the composition as defined in any one of claims 1 to 5, preferably pressurized at a pressure of 3x 105 Pa to 1.5 x107 Pa.
    [0007]
    7. Simulated cigarette, characterized in that it comprises: a housing; a pressurized reservoir of inhalable composition within the housing; an outlet for the inhalable composition from the reservoir and out of the housing, the outlet being configured to eject inhalable composition from the even in the form of droplets, at least some of the droplets having a diameter of 10 µm or less; and, an outlet valve for controlling the flow of the inhalable composition through the outlet, wherein the inhalable composition is as defined in any one of claims 1 to 5.
    [0008]
    8. Simulated cigarette according to claim 7, characterized in that: the outlet valve is a valve activated by breathing.
    [0009]
    9. A simulated cigarette according to any one of claims 7 or 8, characterized in that it additionally comprises a capillary plug extending from the region of the outlet valve into the reservoir, filling at least 50% of the reservoir volume and being configured to capillary absorb the inhalable composition towards the outlet.
    [0010]
    10. A simulated cigarette according to claim 8, characterized in that the housing has an outlet end and an opposite end and wherein the simulated cigarette further comprises: a composition flow path for composition flow from the reservoir along the flow path and out of the outlet at the outlet end of the housing; a flexible diaphragm within the housing defining an air flow path from an air inlet to an air outlet at the outlet end of the housing; a valve element movable with the diaphragm and prompted by a pulling force in a position in which it closes the composition flow path; wherein suction at the outlet end causes a flow through the air flow path providing a pressure differential over the valve element, thereby lifting the valve element against the request force to open the composition flow path; ewhere the pull force is arranged to close the flow path of the composition once the suction ceases.
    [0011]
    11. A simulated cigarette according to claim 8, characterized in that the breath activated valve is an uncalibrated valve between the outlet and the reservoir, the breath activated valve comprising a flow path extending from the reservoir to the outlet end, at least a portion of the flow path being a deformable tube, and a clamping member which clamps the deformable tube closed when no suction force is applied to the device and releases the tube to open the flow path when the suction is applied to the outlet to provide uninterrupted flow from the reservoir to the outlet.
    [0012]
    12. A simulated cigarette according to any one of claims 7 to 11, characterized in that it additionally comprises: a refill valve in communication with the reservoir through which the reservoir can be recharged; and/or, in which the size of the reservoir, the pressure within the reservoir and the size of the outlet at its narrowest point are arranged so that when the outlet valve is fully open, the reservoir will discharge in less than 30 seconds ; and/or, which simulated cigarette is configured to eject composition droplets therefrom in which at least 99% of the droplet volume has a diameter of less than 10 µm; and/or, wherein the simulated cigarette is configured to eject composition therefrom at a rate of 0.5 to 3 liters per minute; and/or, wherein the simulated cigarette is configured to provide an inhalation resistance of 1 to 7 kPa; and/or, in which the simulated cigarette is configured to dispense nicotine to a user at a range of 0.01 to 0.06 mg/ml.
    [0013]
    13. Method for manufacturing the composition as defined in any one of claims 1 to 5, characterized in that it comprises: preparing a premix comprising a monohydric alcohol and a glycol or glycol ether, and optionally a receptor agonist TAS2R taste and/or flavoring component, wherein the ratio of monohydric alcohol:glycol or glycol ether by weight is from 3:1 to 1:1; add nicotine or a pharmaceutically acceptable salt thereof to the premix to obtain a nicotine-containing mixture; and adding a propellant to the nicotine-containing mixture, preferably wherein the composition comprises a TAS2R taste receptor agonist and/or flavoring component, and wherein the monohydric alcohol and the glycol or glycol ether are combined before the TAS2R taste receptor agonist and / or flavoring component is added.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112015004231B1|2021-06-08|inhalable composition, pressurized container, simulated cigarette, and, method of making a composition
    GB2542404B|2019-08-14|An inhalable composition and an inhaler
    AU2008269573B2|2013-09-05|An inhalable composition comprising nicotine
    US10413521B2|2019-09-17|Cannabinoid compositions and uses
    US20060018840A1|2006-01-26|Aerosolizable formulation comprising nicotine
    PT2186507E|2015-06-24|A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity
    JP2008509197A|2008-03-27|Aerosol formulation for inhalation containing anticholinergics
    JP6503043B2|2019-04-17|Novel propellant containing tiotropium preparations
    US9918961B2|2018-03-20|Cannabinoid inhaler and composition therefor
    US20190124976A1|2019-05-02|Nicotine dosage regimen
    JP2017522293A|2017-08-10|Nicotine administration plan
    US20210093552A1|2021-04-01|Inhalable cannabinoid compositions and uses
    GB2542389A|2017-03-22|Simulated cigarette
    GB2528434A|2016-01-27|Nicotine dosage regimen
    同族专利:
    公开号 | 公开日
    RU2015110686A|2016-10-20|
    AU2013308229A1|2015-04-09|
    RU2662550C2|2018-07-26|
    AR092261A1|2015-04-08|
    AU2013308229B2|2019-05-09|
    CN104768406A|2015-07-08|
    IL237467A|2018-12-31|
    EP2890256A2|2015-07-08|
    PH12015500686A1|2015-06-08|
    US9655890B2|2017-05-23|
    ZA201502013B|2016-10-26|
    PH12015500686B1|2015-06-08|
    KR20150046318A|2015-04-29|
    IN2015DN02328A|2015-08-28|
    IL237467D0|2015-04-30|
    HK1211188A1|2016-05-20|
    WO2014033437A2|2014-03-06|
    NZ706361A|2018-05-25|
    CL2015000486A1|2015-10-02|
    JP6185067B2|2017-08-23|
    DK2890256T3|2022-01-17|
    TWI612979B|2018-02-01|
    KR102256326B1|2021-05-26|
    JP2015527071A|2015-09-17|
    CA2883379A1|2014-03-06|
    MX2015002476A|2015-06-05|
    US20150297580A1|2015-10-22|
    WO2014033437A3|2014-06-26|
    EP2890256B1|2021-10-27|
    CN104768406B|2018-11-16|
    UA115671C2|2017-12-11|
    TW201410274A|2014-03-16|
    BR112015004231A2|2017-07-04|
    CA2883379C|2016-11-15|
    GB201215273D0|2012-10-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1017032A|1963-12-12|1966-01-12|Aerosmoke Ltd|Aerosol compositions|
    JPH0469990B2|1987-07-08|1992-11-09|Dainichi Seika Kogyo Kk|
    US6413496B1|1996-12-04|2002-07-02|Biogland Ireland Limited|Pharmaceutical compositions and devices for their administration|
    SE0201669D0|2002-06-03|2002-06-03|Pharmacia Ab|New formulation and use thereof|
    US20040002520A1|2002-07-01|2004-01-01|Soderlund Patrick L.|Composition and method for cessation of Nicotine cravings|
    CN101084801A|2003-04-29|2007-12-12|韩力|Non-combustible electronic spraying cigarette|
    WO2006004646A1|2004-06-28|2006-01-12|Nektar Therapeutics|Aerosol formulation comprising nicotine salt|
    GB0712308D0|2007-06-25|2007-08-01|Kind Group Ltd|An inhalable composition|
    US20110213021A1|2008-03-04|2011-09-01|Indigene Pharmaceuticals, Inc.|Compositions and methods for treating nos-associated diseases|
    GB0808154D0|2008-05-06|2008-06-11|British American Tobacco Co|Aerosol dispensing device|
    GB0823491D0|2008-12-23|2009-01-28|Kind Consumer Ltd|A simulated cigarette device|
    CN102080276B|2009-11-30|2014-05-14|合肥中科绿色家电科技有限公司|Biodegradable cigarette fiber material and cigarette filter tip|
    GB201003552D0|2010-03-03|2010-04-21|Kind Consumer Ltd|A simulated cigarette|
    EP2460422A1|2010-12-03|2012-06-06|Philip Morris Products S.A.|An aerosol generating system with provention of condensate leakage|
    EP2468117A1|2010-12-24|2012-06-27|Philip Morris Products S.A.|An aerosol generating system having means for determining depletion of a liquid substrate|
    CN102266125B|2011-07-28|2013-01-09|易侧位|Health care type traditional Chinese medicine electronic cigarette for quitting smoking|
    US8646461B2|2011-12-14|2014-02-11|Sentiens, Llc|Device and method for simulating chemosensation of smoking|US10279934B2|2013-03-15|2019-05-07|Juul Labs, Inc.|Fillable vaporizer cartridge and method of filling|
    US10244793B2|2005-07-19|2019-04-02|Juul Labs, Inc.|Devices for vaporization of a substance|
    GB2512325B|2013-03-26|2016-06-22|Kind Consumer Ltd|A pressurised refill canister with an outlet valve|
    GB2512326B|2013-03-26|2016-02-24|Kind Consumer Ltd|A pressurised refill canister with an outlet valve|
    GB2514758B|2013-03-26|2015-06-24|Kind Consumer Ltd|A Pressurised Refill Canister with an Outlet Valve|
    EA033402B1|2013-07-19|2019-10-31|Altria Client Services Llc|Liquid aerosol formulation of an electronic smoking article|
    US10512282B2|2014-12-05|2019-12-24|Juul Labs, Inc.|Calibrated dose control|
    US10159282B2|2013-12-23|2018-12-25|Juul Labs, Inc.|Cartridge for use with a vaporizer device|
    US10076139B2|2013-12-23|2018-09-18|Juul Labs, Inc.|Vaporizer apparatus|
    US20160366947A1|2013-12-23|2016-12-22|James Monsees|Vaporizer apparatus|
    HUE053511T2|2013-12-23|2021-07-28|Juul Labs Int Inc|Vaporization device systems|
    US10058129B2|2013-12-23|2018-08-28|Juul Labs, Inc.|Vaporization device systems and methods|
    GB2524469A|2014-02-14|2015-09-30|Kind Consumer Ltd|A cannabinoid inhaler and composition therefor|
    GB2524293B|2014-03-19|2017-12-06|Kind Consumer Ltd|An inhaler|
    EP3129024A4|2014-04-08|2017-11-22|Sansa CorporationInc.|Nicotine formulations and methods of making the same|
    EP3148982A1|2014-05-27|2017-04-05|R. J. Reynolds Tobacco Company|Nicotine salts, co-crystals, and salt co-crystal complexes|
    US10508096B2|2014-05-27|2019-12-17|R.J. Reynolds Tobacco Company|Nicotine salts, co-crystals, and salt co-crystal complexes|
    EP3160273A1|2014-06-25|2017-05-03|Kind Consumer Limited|Nicotine dosage regimen|
    GB2528434A|2014-06-26|2016-01-27|Kind Consumer Ltd|Nicotine dosage regimen|
    GB2530980A|2014-09-19|2016-04-13|Kind Consumer Ltd|Simulated cigarette|
    CN105054281B|2015-07-21|2016-11-23|中国烟草总公司广东省公司|A kind of aerial fog type mouth cigarette|
    US9585835B1|2015-09-16|2017-03-07|Sansa CorporationInc.|Inhalable nicotine formulations and methods of making and using the same|
    US10149844B2|2015-09-16|2018-12-11|Philip Morris Products S.A.|Inhalable nicotine formulations, and methods of making and using thereof|
    US11224594B2|2015-09-16|2022-01-18|Philip Morris Products S.A.|Nicotine formulations and methods of making and using the same|
    GB2542389A|2015-09-17|2017-03-22|Kind Consumer Ltd|Simulated cigarette|
    GB2542404B|2015-09-18|2019-08-14|Kind Consumer Ltd|An inhalable composition and an inhaler|
    GB201516729D0|2015-09-22|2015-11-04|The Technology Partnership Plc|Liquid nicotine formulation|
    CN105455190A|2016-02-01|2016-04-06|湖北中烟工业有限责任公司|Electronic cigarette liquid|
    SG11201806801VA|2016-02-11|2018-09-27|Juul Labs Inc|Securely attaching cartridges for vaporizer devices|
    DE202017007467U1|2016-02-11|2021-12-08|Juul Labs, Inc.|Fillable vaporizer cartridge|
    WO2017149534A1|2016-02-29|2017-09-08|Nicogen Ltd.|Nicotine formulation and aerosols|
    US10405582B2|2016-03-10|2019-09-10|Pax Labs, Inc.|Vaporization device with lip sensing|
    USD849996S1|2016-06-16|2019-05-28|Pax Labs, Inc.|Vaporizer cartridge|
    USD848057S1|2016-06-23|2019-05-07|Pax Labs, Inc.|Lid for a vaporizer|
    USD851830S1|2016-06-23|2019-06-18|Pax Labs, Inc.|Combined vaporizer tamp and pick tool|
    USD836541S1|2016-06-23|2018-12-25|Pax Labs, Inc.|Charging device|
    USD825102S1|2016-07-28|2018-08-07|Juul Labs, Inc.|Vaporizer device with cartridge|
    USD842536S1|2016-07-28|2019-03-05|Juul Labs, Inc.|Vaporizer cartridge|
    USD887632S1|2017-09-14|2020-06-16|Pax Labs, Inc.|Vaporizer cartridge|
    WO2019198162A1|2018-04-10|2019-10-17|日本たばこ産業株式会社|Atomization unit|
    WO2020023535A1|2018-07-23|2020-01-30|Juul Labs, Inc.|Airflow management for vaporizer device|
    US20210386663A1|2020-06-10|2021-12-16|Howard University|Method for treating or mitigating parkinson's disease using nicotine inhaler or nicotine nasal spray|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-11-21| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-01-29| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]|Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
    2020-03-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-11-10| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
    2021-05-11| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-06-08| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2013, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    GBGB1215273.2A|GB201215273D0|2012-08-28|2012-08-28|Nicotine composition|
    GB1215273.2|2012-08-28|
    PCT/GB2013/052231|WO2014033437A2|2012-08-28|2013-08-23|Nicotine composition|
    [返回顶部]